Actively Recruiting
A Clinical Study on Fasudil Hydrochloride for Treatment of Gene-Specific Ovarian Cancer
Led by Zhejiang Provincial People's Hospital · Updated on 2025-03-24
20
Participants Needed
1
Research Sites
143 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a prospective study investigating whether the research on Fasudil Hydrochloride in the treatment of gene-specific ovarian cancer can be applied to predict sensitivity to immunotherapy in non-small cell lung cancer (NSCLC) and other tumors. The study plans to enroll 20 patients with A/A genotype ovarian cancer for treatment evaluation.
CONDITIONS
Official Title
A Clinical Study on Fasudil Hydrochloride for Treatment of Gene-Specific Ovarian Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients voluntarily participate in the study, sign informed consent forms, and have good compliance
- Ovarian cancer patients who have completed platinum-based chemotherapy at Zhejiang Provincial People's Hospital
- Patients with disease stability (SD) or disease progression (PD) twice after chemotherapy
- Confirmed A/A genotype of ovarian cancer through genetic testing
You will not qualify if you...
- Patients with hypotension
- Patients with bleeding disorders such as cerebral hemorrhage
- Patients with abnormal liver function
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, China
Actively Recruiting
Research Team
Y
Yang Liu, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here